Metastasis is a complex multistep process that begins with the epithelial-mesenchymal transition (EMT). Circulating tumor cells (CTCs) are believed to have undergone EMT and thus express low levels or lack epithelial markers commonly used for enrichment and/or detection of such cells. However, most current methods only target EpCAM and/or cytokeratin to enrich epithelial CTCs, resulting in failure to recognize other, perhaps more important, CTC phenotypes that lack expression of these markers. Here, we describe a population of complex aneuploid CTCs that do not express cytokeratin or CD45 antigen in patients with breast, ovarian, or colorectal cancers. These cells were not observed in healthy subjects. We show that the primary epithelial tumors were characterized by similar complex aneuploidy, indicating conversion to an EMT phenotype in the captured cells. Collectively, our study provides a new method for highly efficient capture of previously unrecognized populations of CTCs.
INTRODUCTION
An epithelial-mesenchymal transition (EMT) in cancer is characterized by loss of cell adhesion, repression of E-cadherin, acquisition of mesenchymal markers, increased cell motility, and invasive potential (1) . Though several approaches describing alternative strategies for recovery and detection of CTCs have been reported, the only FDA-approved technique for CTC detection relies on the use of antibodies targeting the epithelial cell adhesion molecule (EpCAM), followed by cytokeratin (CK) and CD45 staining to confirm an epithelial phenotype (2, 3) . These modern enrichment techniques have characterized such CTCs, showing correlation with survival (4) (5) (6) and response to treatment (6, 7) . CTCs can also express biomarkers reflective of the primary tumor and could be useful as a surrogate for tumor biopsy (8, 9) . However, only a small proportion of CTCs are capable of establishing distant metastasis (10, 11) as evidenced by the phenotypic heterogeneity observed among CTCs within patient blood samples (8) . Biological mechanisms, such as EMT, may also result in a spectrum of epithelial marker shedding and a more progressive metastatic phenotype. Yet, these important EMT-derived CTC populations are likely missed by current techniques (12) . In fact, one of the initial reports describing EpCAM levels in various cancer types found that nearly all epithelial tumors have high expression, while tumors of mesenchymal lineage such as melanomas and sarcomas have no expression (13) . It is unknown whether the most invasive and metastasis-primed cells that have undergone EMT (resembling a more mesenchymal phenotype), no longer express EpCAM and/or cytokeratin and thus evade detection with traditional techniques. Importantly, the relative paucity of clinical evidence that such a process exists has called the theory of EMT into question (14) . Thus, the ability to capture post-EMT cells in circulation could have implications for studying the metastatic process as well as clinical management of cancer patients. 
RESULTS

Capture of Carcinoma Cells Independent of EpCAM Expression
We have developed a microfluidic-based system for capture and analysis of rare cells in circulation, including CTCs ( Supplementary Fig. 1a ). The platform is capable of capturing rare cells from blood for subsequent molecular characterization directly within a uniquely designed microchannel ( Supplementary Fig. 1b,c) . Each microchannel consists of a roughly rectangular chamber (40 mm x 12 mm x 55 microns) in which approximately 9000 variable diameter posts are randomly placed to disrupt laminar flow, and maximize the probability of contact between target cells and the posts, which are derivatized with streptavidin, resulting in their capture (15) .
The platform is versatile, permitting assay optimization with flexibility in the number of antibodies selected for capture and detection as well as allowing immediate and direct single-cell microscopic analyses through the transparent microchannel without the need to manipulate cells onto glass slides. This approach utilizes an antibody cocktail that is added directly to cells prior to capture, enabling recovery of variable CTC phenotypes. Briefly, this mixture contains antibodies directed towards a variety of epithelial cell surface antigens (EpCAM, Her2, MUC-1, EGFR, folate binding protein receptor, TROP-2), and mesenchymal or stem cell antigens (c-MET, N-Cadherin, CD318 and mesenchymal stem cell antigen). Each of these antibodies was tested by flow cytometry for reactivity to several well-characterized cancer cell lines (e.g., SKOV3, LnCaP, SKBR3) and shown to be additive in binding to cells (Supplementary Fig. 2 ).
Antibodies were tested to have minimal cross-reactivity to nucleated cells in healthy control blood. Analytical control samples, namely blood from healthy donors spiked with cancer (SKOV3) cells, were run using this antibody mixture to ensure optimal performance in detecting tumor cells (based on cytokeratin staining).
Analytical validation of the platform to demonstrate precision, reliability and reproducibility in recovery and detection of CTCs based on CK+/CD45-/DAPI+ (4ƍ, 6-diamidino-2-phenylindole) Tumor cell capture efficiency was validated through a series of cell spiking experiments. We demonstrate analytical precision in recovery and detection of low to high EpCAM expressing target cells, independent of the number of cells spiked (Fig. 1a) . We further show >95% reproducibility in tumor cell capture with several cell lines (Fig. 1b) . Capture efficiency using the antibody cocktail was demonstrated with low (T24) and medium (SKOV3) EpCAM expressing cell lines (16) . While SKOV3 cells had high capture efficiency with EpCAM alone as well as with cocktail (>80%), T24 capture efficiency was markedly improved from <10% capture with EpCAM only to >80% with antibody cocktail (P = 0.0001; Fig. 1c ).
Next, clinical verification of capture efficiency was tested by examining CTCs in patient samples.
In the first cohort of 21 patients with advanced stage disease, we compared CTC detection with our platform using either EpCAM alone or antibody cocktail (Supplementary Table 1 ). Improved recovery was observed with higher CTC numbers in 14 of 21 samples with the antibody cocktail (P = 0.07). In 100 normal blood controls, only 1 CK+/CD45-/DAPI+ cell was detected, demonstrating high specificity of the staining procedure. In the second, larger cohort of 93 patients with advanced stage lung, breast, colorectal or prostate cancer, we compared CellSearch® and our platform using the antibody cocktail for capture. Based on standard CK+/CD45-/DAPI+ stain criteria, our platform was found to be significantly more sensitive for CTC enumeration for colorectal, prostate and lung cancers (Fig. 1d) . To further confirm the use of the FISH-based strategy, we applied the same antibody cocktail capture approach and CTC detection (CK+/CD45-/DAPI+ staining) on samples from patients with advanced ovarian or colorectal cancer. To verify detection of CTCs, we again used FISH, but with the aim to detect aneuploidy (unbalanced genomic copy number changes). We rarely found CK+/CD45-stained cells; roughly 0.1 cells/mL blood of ovarian cancer patients regardless of stage, tumor grade or CA-125 levels (Supplementary Table 2 ). FISH probes targeted to frequently gained genomic regions in ovarian and colorectal carcinoma were chosen based on array comparative genomic hybridization data (18, 19) . Each probe was first tested on a total of 2500 normal peripheral blood cells from five donors and in CK+ cultured SKOV3 cells to determine hybridization efficiency and scoring accuracy in interphase cells captured within the microchannel (see Methods section). Cells that displayed only a monosomic signal for any one of the three probes were excluded (potential signal overlap). Therefore, only cells classified as either trisomic or complex aneuploid (at least one locus gain and another gain or loss at a second locus) were enumerated. As observed with the Her2 positive breast cancer cohort, for both ovarian and colorectal cancer, we found that not only captured CK+/CD45-cells (Fig. 2c) , but also co-captured CK-/CD45-staining cells (Fig. 2d, Supplementary Tables 3,4 ) had complex aneuploidy. Complex aneuploidy was not observed among normal control blood samples.
Similar to breast cancer, when assessing for frequency of complex aneuploidy, colorectal and ovarian cancer patients had nearly the same number of CK-as CK+ CTCs (Fig. 2e,f) . Thus, the presence of CK-complex aneuploid cells further demonstrates the inefficiency of CK as a marker to detect all candidate CTCs.
Cytokeratin-Negative CTCs Found within the Primary Tumor
We hypothesized that if the isolated CK-CTCs are the consequence of EMT then similar cells should be present within the primary tumor. We sought to verify that the circulating aneuploid cells identified in ovarian cancer patients had molecular features reflective of the primary tumor and, thus, a useful population of CTCs. Blood was collected from 7 patients just before cytoreductive surgery. Multiple regions in the matched tumor and CTCs shared similar complex aneuploid patterns (Fig. 3a) . Interestingly, about 20% of these aneuploid regions within the tumor were cytokeratin-negative and were heterogeneous in distribution (Fig. 3b) . Although similar findings using FISH in CTCs and CECs compared to primary tumors have been described (20) , these were based on circulating CK+ cells.
Linking CK-CTCs to an Epithelial-Mesenchymal Transition
One possible mechanism giving rise to presence of CK-CTCs is EMT, a biological process reported to play a significant role in tumor progression and metastasis. Thus, there is growing interest in methods that enable capture and analysis of EMT-derived CTCs. To determine if our assay captures cells that have undergone EMT, we studied the effect of TGF-beta treatment on SKOV3 ovarian carcinoma cells. After 72 hours of treatment, CK staining was lost in about 20% of cells, correlating with an EMT morphologic change (Fig. 4a) . Quantitative PCR analysis of these cells before and after TGF-beta treatment showed an increase in expression of mesenchymal markers (Fig. 4b) . Cells, before and after treatment, were spiked ex vivo into mouse blood and run through the microchannel. All untreated cells captured were CK+, however, after TGF-beta treatment, 16% of the cells captured were CK-and had complex aneuploidy (Fig. 4c) . Direct visualization of the FISH staining within the microchannel demonstrates these CK+ and CK-cells had nearly identical complex aneuploid patterns (Fig.   4d ).
Next, to examine the utility of our CTC detection system for capturing tumor cells with EMT features in an in vivo setting, we studied the effect of TGF-beta treatment on HeyA8 ovarian carcinoma cells. After 72 hours of TGF-beta treatment, approximately 50-60% of cells lost their CK staining (Fig. 4e) . To determine if these CK-cells can be captured in circulation, we established a metastatic orthotopic model with HeyA8 cells. Ten tumor-bearing mice were monitored for signs of morbidity, at which point approximately 350 μL of blood was obtained per mouse by cardiac puncture prior to sacrifice. All sites of metastatic tumor were carefully removed and weighed. Both CK+ and CK-complex aneuploid CTCs were isolated from circulation within the microchannel (Fig. 4f) . Enumeration of complex aneuploid CK-CTCs correlated with aggregate tumor burden (Fig. 4g ).
Discussion
Collectively, these results confirm the utility of our microfluidics platform as a reliable method for assay development and for efficient recovery of CTCs. We observed that a potentially important There are some recent reports of isolated CTCs expressing markers of EMT. For example, in metastatic breast cancer patients receiving standard therapies, CTCs correlated with more frequent expression of EMT markers (Twist1, Akt2 and PI3K-alpha) in those who were resistant to treatment (22) . Similar reports have found that CTCs can co-express both epithelial (cytokeratin and e-cadherin) and mesenchymal (vimentin and n-cadherin) markers (23, 24 ).
Likewise, a higher incidence of CK+Vimentin+ and CK+Twist+ CTCs was found in metastatic breast cancer patients versus women with earlier stage disease (25) . These studies suggest a continuum in the spectrum of epithelial differentiation to mesenchymal phenotype, suggesting that CTCs may have a partial EMT phenotype (12) . However, these platforms may miss clinically relevant populations of CTCs because they rely upon cytokeratin for CTC detection. To our knowledge, we provide the first report linking CK-CTCs to EMT.
Although the antibodies used in our study detect a wide range of cytokeratins, it is possible that these antibodies may not detect all cytokeratins. Thus, it is possible that the complex aneuploid CK-CTCs we detected may still express other cytokeratins. There is increasing evidence that different CK antibodies detect different subsets of CTCs. Currently, different groups are targeting a variety of cytokeratins for detection of CTCs, such as cytokeratins 8, 18 and 19 (26-28) and cytokeratins 7 and 8 (2, 29) . However, there is increasing concern that targeting only a few cytokeratins for CTC detection, such as cytokeratin 18 (30) 
METHODS
